valneva se glp-1 receptor agonist weight management diabetes treatments cardinal health GLP-1 Agonists: Revolutionizing the Treatment of Obesity, but Are They Enough? - Eric Velazquez, MD - Bariatric Surgeon GLP-1 receptor agonists are increasingly

Shima Hadidchi

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

Official supply shortages persisted for most of 2024, as surging demand for AOMs continued to outstrip product supply, despite limited reimbursement, which presented an opportunity quickly seized upon by U.S

Ph 2 datathat showed weight loss of between 9.4% and 14.7% after 36 weeks on the drug compared to 2.3% for the placebo group and is currently in Ph 3

Patients who suffer from the adverse effects of the weight loss injections may file for compensation